Development, stability and in vitro permeation studies of gels containing mometasone furoate for the treatment of dermatitis of the scalp

Brazilian Journal of Pharmaceutical Sciences

Volumn 46, Issue 1, 2010, Pages 109-114

  Salgado, Ana Cristina Gomes Barros ^a   Da Silva, Alexandra Maria Nunes Nogueira ^a   Machado, Marta Cristina Jorge Cabral ^a   Duarte, Maria Aida Da Silva Costa ^a   Ribeiro, Helena Margarida De Oliveira Marques ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Dermatitis treatment; Gel development; Gels stability; Mometasone furoate; Skin permeation in vitro study

Indexed keywords

MOMETASONE FUROATE;

ADULT; ARTICLE; CASE REPORT; DERMATITIS; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; GEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MICROBIOLOGY; PERMEABILITY; PH; SCALP DERMATITIS; VISCOSITY; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PURIFICATION; DRUG SOLUBILITY; FLOCCULATION; FLOW KINETICS; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN CELL; MEMBRANE PERMEABILITY; MOLECULAR STABILITY; ORGANOLEPTIC PROPERTY; PHYSICAL CHEMISTRY; SCALP; STRATUM CORNEUM;

EID: 77953235909     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/S1984-82502010000100012     Document Type: Article

References (16)

1. AGNER, T. Compliance among patients with atopic eczema. Acta Derm. Venereol., n.215, supl., p.33-35, 2005.
2. FARMACOPEIA PORTUGUESA VIII, Lisboa: INFARMED/Ministério da Saúde e Instituto Nacional da Farmácia e do Medicamento, 2005. p.157-159.
3. FERRÃO, E.; SALGADO, A.; BRONZE, M. R.; RIBEIRO, H. Desenvolvimento e avaliação sensorial de formulações para aplicação no couro cabeludo. Rev. Lusóf. Ciên. Tec. da Saúde, v.4, n.1 p.242-250, 2007.
4. GUIDELINE EMEA. Stability testing: of existing active substances and related finished products. issued as CPMP/QWP/122/02, 2003. p. 5-13.
5. GUIDELINE ICH. Q2 (R1), Validation of analytical procedures: Text and methodology. EU: Adopted by CPMP, November 94, issued as CPMP/ICH/381/95, 2005. p.2-15.
6. HADGRAFT, J.; LANE, M. Skin permeation: the years of enlightenment. Int. J. Pharmaceutics, v.305, n.1-2, p.2-12, 2005.
7. HANIFIN, J. M.; COOPER, K. D.; HO, V. C. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology. J. Am. Acad. Dermatol., v.50, suppl. 3, p.391-404, 2004.
8. HERKENNE C., NAIK A., KALIA Y. N., HADGRAFT J., GUY R. H. Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J. Invest. Dermatol., v.127, número?, p.887-894, 2007.
9. KODA, K.; YOUNG, L., KRADJAN W., GUGLIELMO J., ALLDREDGE B., CORELLI R., WILLIAMS B. Applied therapeutics: the clinical usage of drugs. 8.ed. Lippincott: Williams & Wilkins, 2004. p.38-39.
10. MAGNUSSON B. M., CROSS S. E., WINCKLE G., ROBERTS M. S. Determination of in vitro permeability and tissue reservoir characteristics in human skin layers. Skin Pharmacol. Physiol., v.19, n.6, p.336-342, 2006.
11. MARKS, R.; PONGSEHIRUM, D.; SAYLAN, T. A method for the assay of topical corticosteroids. Br. J. Dermatol., volume?, n.88, p.69-74, 1973.
12. PELLANDA C. L. Topical bioavailability of glucocorticosteroids. Dermatopharmacokinetic and dermatopharmacodynamic of topically applied triamcinolone acetonide in humans. Basel, 2006. p.41-42. [Tese Doutoramento. Hospital Pharmacy.Universidade Basel].
13. TENG, X.W.; CUTLER, D. C.; DAVIES, N. M. Degradation kinetics of mometasone furoate in aqueous systems. Int. J. Pharmaceutics, v.259, n.1, p.129-141, 2003.
14. THESTRUP-PEDERSEN, K. Treatment strategies and compliance for the adult patient with atopic eczema, Acta Derm. Venereol., v.85, n.5, supl.215, p.36-40, 2005.
15. VALOTIS, A., NEUKAM K., ELERT O., HÖGGER P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J. Pharm. Sci., v.93, n.5, p.1337-1350, 2004.
16. WIEDERSBERG, S.; LEOPOLD, C. S.; GUY, R. H. Bioavailability and bioequivalence of topical glucocorticoids. Eur. J. Pharm. Biopharm., v.68, n.3, p.453-466, 2008.